Printer Friendly

ENDOTRONICS, INC. UPGRADES PRODUCTION FACILITY AND SIGNS CYTOGEN CORPORATION CONTRACT

 MINNEAPOLIS, Jan. 29 /PRNewswire/ -- Endotronics, Inc. (NASDAQ: ENDO) announced today that it has filed a Type I Drug Master File with the Food and Drug Administration that describes the procedures, equipment, and facilities that Endotronics now has in place to be able to to offer contract manufacture of clinical grade biopharmaceuticals. This was one of the many steps Endotronics took in 1992 to upgrade its contract production services of monoclonal antibodies for human injectable products which includes in vivo diagnostics and therapeutics.
 Richard E. Sakowicz, president and chief operating officer of Endotronics, commented: "Endotronics has provided production equipment and contract production services for in vitro diagnostic and research products for several years. Our customers include the top 10 pharmaceutical and biotechnology companies, and many prestigious research institutions. Among the commercial biotech companies, Cytogen Corporation is the first to contract this growing part of Endotronics' business to produce several trial batches of two of their monoclonal antibodies for cancer detection for use in clinical programs. Cytogen intends to include the Endotronics ACUSYST(R) and OPTICELL(TM) technologies in their Princeton, N.J. manufacturing facility."
 Endotronics, Inc., headquartered in Minneapolis, is dedicated to providing cell culture processing services to meet the needs of human health-care and biotechnology markets worldwide. The company is a recognized industry leader in mammalian cell culture instrumentation with more than 700 research/pilot scale and over 100 production scale instruments sold worldwide since 1986.
 -0- 1/29/92
 /CONTACT: Yvonne L. Marschner-Bova, director, Investor Relations, Endotronics, 313-871-7350/
 (ENDO)


CO: Endotronics, Inc. ST: Minnesota IN: MTC SU: CON

KR -- DE008 -- 0633 01/29/93 09:25 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 29, 1993
Words:268
Previous Article:ROCKWELL INTRODUCES NEW LINE OF 10-SPEED TRANSMISSIONS
Next Article:MICHIGAN RIVET REPORTS EARNINGS
Topics:


Related Articles
ENDOTRONICS, INC. SIGNS AGREEMENT WITH GOODWIN INSTITUTE FOR CANCER RESEARCH INC. TO EXPAND CONTRACT PRODUCTION SERVICES
ENDOTRONICS HOLDS ANNUAL MEETING OF SHAREHOLDERS: UPDATES INVESTMENT COMMUNITY ON ACUMOUSE AND ARTIFICIAL LIVER PROGRAM
ENDOTRONICS SIGNS PRODUCTION AND MARKETING AGREEMENT WITH HELIXYS
CYTOGEN AND CHIRON EXPAND EUROPEAN MARKETING AGREEMENT
ENDOTRONICS, INC. AND WHEATON SCIENCE PRODUCTS, INC. ANNOUNCE MARKETING AND DISTRIBUTION AGREEMENT
ENDOTRONICS, INC. SIGNS STRATEGIC COOPERATION AGREEMENT WITH TECNOMARA AG OF SWITZERLAND
ENDOTRONICS REPORTS FOURTH-QUARTER AND FISCAL 1992 YEAR-END RESULTS
ENDOTRONICS REPORTS RESULTS FOR ITS FIRST QUARTER ENDED DEC. 31, 1992
ENDOTRONICS, INC. ANNOUNCES REALIGNMENT; HORWATH PROMOTED TO VICE PRESIDENT AND GENERAL MANAGER OF BIOPROCESSING BUSINESS UNIT
CELLCOR TO MANUFACTURE NEOPROBE'S CELL THERAPY PRODUCT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters